Emapalumab MDA5 Rapidly Progressive Interstitial Lung Disease (RP-ILD) Study

NCT07486869 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

5

Enrollment

OTHER

Sponsor class

Conditions

Dermatomyositis
Dermatomyositis Sine Myositis
Dermatomyositis With Myopathy
Dermatomyositis With Respiratory Involvement
Dermatomyositis With Organ Involvement
Interstitial Lung Disease
Interstitial Lung Disease Due to Connective Tissue Disease (Disorder)

Interventions

DRUG: Emapalumab

Sponsor

University of Miami

Collaborators

[object Object]